Are anti-inflammatory agents and nutraceuticals - novel inhibitors of PCSK9?

Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a protease which increases the lysosomal degradation of low density lipoprotein receptor (LDLR) resulting in elevated serum LDL-cholesterol levels. Elevated LDL-cholesterol is the main risk factor for cardiovascular disease (CVD). Antibodies t...

Full description

Saved in:
Bibliographic Details
Published in:Critical reviews in food science and nutrition 2021, Vol.61 (2), p.325-336
Main Authors: Shafabakhsh, Rana, Reiner, Željko, Hallajzadeh, Jamal, Mirsafaei, Liaosadat, Asemi, Zatollah
Format: Article
Language:English
Subjects:
Anti-Inflammatory Agents
Antibodies
cardiovascular disease
Cardiovascular diseases
Cholesterol
Cholesterol, LDL
Dietary Supplements
Dyslipidemia
Functional foods & nutraceuticals
Heart diseases
Inflammation
inflammatory markers
Kexin
LDL-cholesterol
Lipids
Low density lipoprotein
Low density lipoprotein receptors
Lysosomes
Metabolic disorders
Molecular modelling
nutraceuticals
Proprotein Convertase 9
Proprotein convertase subtilisin/kexin type 9
Proprotein convertases
Receptor density
Risk analysis
Risk factors
Subtilisin
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a protease which increases the lysosomal degradation of low density lipoprotein receptor (LDLR) resulting in elevated serum LDL-cholesterol levels. Elevated LDL-cholesterol is the main risk factor for cardiovascular disease (CVD). Antibodies to PCSK9 decrease LDL-cholesterol. Recent studies have suggested a direct relationship between PCSK9 and inflammation and the potential inhibitory effects of anti-inflammatory agents against this enzyme. Nutraceuticals are natural compounds, which have numerous anti-inflammatory and lipid-lowering effects. In this review we focus on anti-inflammatory substances and nutraceuticals, which are beneficial in treatment of dyslipidemia. We also reviewed the recent findings concerning the role of PCSK9 as the main target for molecular mechanisms of these substances.
ISSN:1040-8398
1549-7852
DOI:10.1080/10408398.2020.1731678